Wilkerson J - Search Results

1

Neutral evolution of drug resistant colorectal cancer cell populations is independent of their KRAS status.

Blagoev KB, Wilkerson J, Burotto M, Kim C, Espinal-Domínguez E, García-Alfonso P, Alimchandani M, Miettinen M, Blanco-Codesido M, Fojo T. Blagoev KB, et al. Among authors: wilkerson j. PLoS One. 2017 Oct 5;12(10):e0175484. doi: 10.1371/journal.pone.0175484. eCollection 2017. PLoS One. 2017. PMID: 28981524 Free PMC article.

2

Progression-free survival is simply a measure of a drug's effect while administered and is not a surrogate for overall survival.

Wilkerson J, Fojo T. Wilkerson J, et al. Cancer J. 2009 Sep-Oct;15(5):379-85. doi: 10.1097/PPO.0b013e3181bef8cd. Cancer J. 2009. PMID: 19826357 Review.

3

Continuing a cancer treatment despite tumor growth may be valuable: sunitinib in renal cell carcinoma as example.

Burotto M, Wilkerson J, Stein W, Motzer R, Bates S, Fojo T. Burotto M, et al. Among authors: wilkerson j. PLoS One. 2014 May 5;9(5):e96316. doi: 10.1371/journal.pone.0096316. eCollection 2014. PLoS One. 2014. PMID: 24796484 Free PMC article. Clinical Trial.

4

Therapies with diverse mechanisms of action kill cells by a similar exponential process in advanced cancers.

Blagoev KB, Wilkerson J, Stein WD, Yang J, Bates SE, Fojo T. Blagoev KB, et al. Among authors: wilkerson j. Cancer Res. 2014 Sep 1;74(17):4653-62. doi: 10.1158/0008-5472.CAN-14-0420. Cancer Res. 2014. PMID: 25183789 Free PMC article.

5

Hazard ratios in cancer clinical trials--a primer.

Blagoev KB, Wilkerson J, Fojo T. Blagoev KB, et al. Among authors: wilkerson j. Nat Rev Clin Oncol. 2012 Jan 31;9(3):178-83. doi: 10.1038/nrclinonc.2011.217. Nat Rev Clin Oncol. 2012. PMID: 22290283 Free PMC article. Review.

6

Gefitinib and erlotinib in metastatic non-small cell lung cancer: a meta-analysis of toxicity and efficacy of randomized clinical trials.

Burotto M, Manasanch EE, Wilkerson J, Fojo T. Burotto M, et al. Among authors: wilkerson j. Oncologist. 2015 Apr;20(4):400-10. doi: 10.1634/theoncologist.2014-0154. Epub 2015 Mar 20. Oncologist. 2015. PMID: 25795635 Free PMC article.

7

Phase II Clinical Trial of Ixabepilone in Metastatic Cervical Carcinoma.

Burotto M, Edgerly M, Poruchynsky M, Velarde M, Wilkerson J, Kotz H, Bates S, Balasubramaniam S, Fojo T. Burotto M, et al. Among authors: wilkerson j. Oncologist. 2015 Jul;20(7):725-6. doi: 10.1634/theoncologist.2015-0104. Epub 2015 Jun 3. Oncologist. 2015. PMID: 26040622 Free PMC article. Clinical Trial.

8

Adjuvant and neoadjuvant cancer therapies: A historical review and a rational approach to understand outcomes.

Burotto M, Wilkerson J, Stein WD, Bates SE, Fojo T. Burotto M, et al. Among authors: wilkerson j. Semin Oncol. 2019 Feb;46(1):83-99. doi: 10.1053/j.seminoncol.2019.01.002. Epub 2019 Jan 26. Semin Oncol. 2019. PMID: 30738604 Review.

9

Colorectal Cancer Survival Gains and Novel Treatment Regimens: A Systematic Review and Analysis.

Jawed I, Wilkerson J, Prasad V, Duffy AG, Fojo T. Jawed I, et al. Among authors: wilkerson j. JAMA Oncol. 2015 Sep;1(6):787-95. doi: 10.1001/jamaoncol.2015.1790. JAMA Oncol. 2015. PMID: 26181239

10

Stable disease is not preferentially observed with targeted therapies and as currently defined has limited value in drug development.

Vidaurre T, Wilkerson J, Simon R, Bates SE, Fojo T. Vidaurre T, et al. Among authors: wilkerson j. Cancer J. 2009 Sep-Oct;15(5):366-73. doi: 10.1097/PPO.0b013e3181b9d37b. Cancer J. 2009. PMID: 19826355 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

451 results

Search Page

Filters